In vivo production of psilocybin in E. coli
Metabolic Engineering September 21, 2019 Alexandra M. Adams, Nicholas A. Kaplan, Zhangyue Wei et al. 83 citations
A modular biosynthetic production platform for psilocybin was developed in the model microbe Escherichia coli. Multiple genetic optimization techniques improved psilocybin titer by 32-fold. Further fermentation optimization in a fed-batch study achieved a production titer of 1.16 g/L of psilocybin, the highest titer reported from a recombinant organism to date. This work demonstrates progress toward the industrial bioproduction of psilocybin for clinical use.